Landiolol hydrochloride is a newly developed cardioselective, ultra short-acting b 1 -adrenergic receptor blocking agent. Landiolol hydrochloride has much higher cardioselectivity (b 1 /b 2 ϭ255) than currently available b 1 -blockers, such as esmolol hydrochloride (b 1 /b 2 ϭ33).
Landiolol hydrochloride is a newly developed cardioselective, ultra short-acting b 1 -adrenergic receptor blocking agent. Landiolol hydrochloride has much higher cardioselectivity (b 1 /b 2 ϭ255) than currently available b 1 -blockers, such as esmolol hydrochloride (b 1 /b 2 ϭ33). 1) This drug is rapidly hydrolyzed by both carboxylesterase in the liver and pseudocholinesterase in the plasma 2) to an inactive metabolite (M-1) with a rapid elimination half-life of about 4 min, which is significantly shorter than the elimination half-lives of conventional b 1 -blockers.
3) Based on these features, landiolol hydrochloride has been used in the emergency management of atrial fibrillation, atrial flutter and tachycardia as well as in perioperative arrhythmia control.
The introduction of a target controlled infusion (TCI) system into clinical practice ensures that a target plasma drug concentration is obtained to induce and maintain anesthesia during perioperative anesthetic management. Based on a pharmacokinetic model, the TCI system determines the initial loading dose needed to achieve a target plasma drug concentration and the infusion rate needed to maintain a constant concentration, and controls the intravenous infusion completely automatically. 4) Therefore, application of the TCI system to landiolol hydrochloride administration is expected to allow more effective and safe drug administration.
After the quantitation of landiolol in blood, establishing the pharmacokinetic model is necessary for the application of the TCI system. About the quantitation method of landiolol and its major metabolite, although the summarized method was already reported, 5, 6) the method details and validation data had not been reported.
In this report, validated HPLC-UV methods that quantitatively determine landiolol and its major metabolite in human blood were reported in order to contribute to progress of clinical research of landiolol hydrochloride such as the application of the TCI system.
MATERIALS AND METHODS

Chemical and Reagents
Landiolol, M-1, an internal standard for landiolol (IS-1), and an internal standard for M-1 (IS-2) were synthesized at Ono Pharmaceutical Co., Ltd. Methanol, ethanol, acetonitrile, ethyl acetate were HPLC grade, and all other reagents were analytical grade. Water was purified by a Mill-Q-System from Yamato Scientific Corp. (Tokyo, Japan). Human blood was collected from healthy volunteers. Bond Elut C 18 (500 mg/3 ml) was obtained from Varian, Inc. (Milford, MA, U.S.A.).
Instrumentation The HPLC system, a LC-10A system (Shimadzu Co., Kyoto, Japan), consisted of an HPLC pump (LC-10AD), an autosampler (SIL-10A), a column heater (CTO-10AC) and a UV detector (SPD-10A).
Liquid Chromatography Chromatographic conditions were applied separately to the two methods for determining landiolol (method 1) and M-1 (method 2). In method 1, an HPLC column, TSK-gel ODS-80TM (5 mm, 4.6 mm inside diameter (i.d.)ϫ250 mm, Tokyo Chemical Industry Co., Ltd., Tokyo, Japan), was used with a guard column TSK-guardgel ODS-80TM (5 mm, 3.2 mm i.d.ϫ15 mm, Tokyo Chemical Industry Co., Ltd.). The mobile phase consisted of potassium dihydrogen phosphate (pH 3; 0.02 mmol/l)-acetonitrile (3 : 1, v/v). The flow rate was 0.8 ml/min, and the column temperature was maintained at 40°C. The autosampler temperature was set to 4°C, and the detection wavelength was 225 nm. The total run time was 35 min for each injection. In method 2, an HPLC column, YMC-AM-302 (5 mm, 4.6 mm i.d.ϫ 150 mm, YMC Co., Ltd., Kyoto, Japan), was used with a guard column YMC-AM-302 (5 mm, 4.6 mm i.d.ϫ10 mm, YMC Co., Ltd.). The mobile phase consisted of potassium dihydrogen phosphate (pH 2.5; 0.02 mmol/l)-methanol-acetonitrile (7 : 2 : 0.3, v/v/v). The flow rate was 0.8 ml/min, and the column temperature was maintained at 25°C. The autosampler was set to ambient temperature, and the detection wavelength was 225 nm. The total run time was 35 min for each injection.
Stock Solutions and Working Solutions A standard landiolol stock solution was prepared in ethanol at a concentration of 100 mg/ml. The stock solution was serially diluted with ethanol to obtain working solutions for standard samples (0.5, 1, 2, 5, 10, 20, 50 mg/ml) and quality control (QC) samples (0.5, 1, 20, 80 mg/ml). A 500 mg/ml standard M-1 stock solution was prepared in water and then serially diluted with ethanol to obtain working solutions for standard samples (1, 2, 5, 10, 20, 50, 100, 200 mg/ml) and QC samples (1, 2, 50, 160 mg/ml). A 400 mg/ml stock solution of IS-1 was prepared in ethanol and then serially diluted with ethanol to obtain a working solution (10 mg/ml). A 300 mg/ml stock solution of IS-2 was prepared with water and then serially diluted with ethanol to obtain a working solution (30 mg/ml). All solutions were stored at Ϫ20°C.
Preparation of Standards and QC Samples To obtain calibration samples ranging from 0.05 to 10 mg/ml for landiolol and 0.1 to 20 mg/ml for M-1, the following reagents were mixed in a glass tube: 1 ml of human blood, 8 ml of ethanol, 100 ml of each working landiolol solution, and 100 ml of each working M-1 solution. For blank and double blank samples, 200 and 400 ml of ethanol were added, respectively, instead of the standard and IS working solutions. QC samples ranging from 0.05 to 8 mg/ml for landiolol and 0.1 to 16 mg/ml for M-1 were prepared in the same manner as the standard samples. Calibration standards were freshly prepared. QC samples were stored at Ϫ20°C until analysis.
Sample Preparation Sample preparation procedure was shown in Fig. 2 . Because landiolol is hydrolyzed very rapidly in blood, 1 ml of blood was placed into an ice-cold tube and mixed quickly with 8 ml ethanol in order to inhibit serum pseudocholinesterase activity. To calibrate standards and QC samples, 100 ml of IS-1 and 100 ml of IS-2 were added and centrifuged (1600 g for 10 min, 4°C). The supernatant was transferred to a glass tube containing 100 ml of 5% propylene glycol in methanol and 100 ml of 0.1% ascorbic acid in methanol. The supernatant was dried under nitrogen at 40°C, and the remaining residue was reconstituted in 3 ml of 1% acetic acid. Each sample was applied to Bond Elut C 18 (500 mg/3 ml) pre-conditioned with 3 ml of methanol, followed by water, and then 1% acetic acid. Following sample loading, the column was washed sequentially with 10 ml of water and 2 ml of acetonitrile. Samples were eluted with 3 ml of 1% ammonia methanol into a glass tube containing 100 ml of 5% propylene glycol in methanol. The eluate was dried under nitrogen at 40°C. The residue was reconstituted in 1 ml of 1% acetic acid, 3 ml of ethyl acetate was then added, and the mixture was mixed for 10 min. The sample was then centrifuged (1600 g for 5 min, 4°C). The organic layer was discarded, and 200 ml of 0.3 mol/l sodium carbonate solution was added to the water layer. The mixture was extracted three times with 3 ml of ethyl acetate (mixed for 10 min, centrifuged at 1600 g for 5 min). The combined organic layer was transferred to a clean glass tube containing 100 ml of 5% propylene glycol in methanol and 100 ml of 0.1% ascorbic acid in methanol. The organic layer was dried under nitrogen at 40°C, and the remaining residue was reconstituted in 50 ml of acetonitrile and 150 ml of water. A 30 ml aliquot was injected into the HPLC to determine landiolol. After three extractions, 1 ml of 0.1 mol/l hydrochloric acid was added to the water layer. The water layer was evaporated under decompression conditions at 40°C for 30 min. Water was added to the water layer up to about 2 ml, and 50 ml of 0.5 mol/l hydrochloric acid was added. Each acid solution was applied to Bond Elut C 18 (500 mg/3 ml) pre-conditioned with 3 ml of methanol and water. Following sample loading, the column was washed sequentially with 10 ml of water and 2 ml of acetonitrile, and then eluted with 3 ml of 1% ammonia methanol into a glass tube. The eluate was dried under nitrogen at 40°C. The residue was reconstituted in 500 ml of 1% acetic acid, and a 30 ml aliquot was injected into the HPLC to determine M-1.
Validation Procedure The analytical method was validated according to FDA guidance.
7) The validation parameters included specificity, linearity, intra-and inter-assay precision and accuracy, extraction recovery, and stability. The specificity of the method was assessed by analyzing blank blood and landiolol and M-1 spiked blood from six individuals. The chromatograms were examined to determine the presence of any endogenous constituents, which could potentially interfere with the analysis of landiolol, IS-1, M-1 and IS-2. Extraction recoveries were performed in triplicate at concentrations of 0.1, 2, and 8 mg/ml for landiolol, 0.2, 5, and 16 mg/ml for M-1, and 1 and 3 mg/ml for IS-1 and IS-2, respectively. Intra-and inter-assay precision [expressed as the percentage coefficient of variation, CV (%)] and accuracy [expressed as the relative error from the nominal concentration, RE (%)] were determined by analyzing three separate analytical batches, including standards and QC samples. Each batch contained standards consisting of eight points (0.05, 0.1, 0.2, 0.5, 1, 2, 5, and 10 mg/ml for landiolol; 0.1, 0.2, 0.5, 1, 2, 5, 10, and 20 mg/ml for M-1), two blanks (blank and double blank), and four concentrations of QC samples (0.05, 0.1, 2, and 8 mg/ml for landiolol; 0.1, 0.2, 5, and 16 mg/ml for M-1) in five replicates for each concentration. Calibration curves were established by linear leastsquares regression (1/y weighting) from peak area ratios versus nominal concentrations. Intra-and inter-assay experiments had Յ15% CV and RE, except for the lower limit of quantification (LLOQ), where Յ20% was acceptable for all parameters. The short-term stability at room temperature for 4 h, and the long-term stability (4 months at Ϫ20°C or Ϫ80°C) were determined for the QC samples. The stability of processed samples was also assessed.
RESULTS AND DISCUSSION
Under optimized HPLC conditions (method 1), landiolol Fig. 2 . Sample Preparation Procedure of Landiolol and M-1 * : glass tube-A containing 100 ml of 5% propylene glycol in methanol and 100 ml of 0.1% ascorbic acid in methanol. * * : pre-conditioned with 3 ml of methanol, followed by water, and then 1% acetic acid. * * * : glass tube-B containing 100 ml of 5% propylene glycol in methanol. * * * * : pre-conditioned with 3 ml of methanol, followed by water.
and IS-1 were separated with retention times of 19.1 and 30.4 min, respectively. Blank human blood from six volunteers showed no significant interfering peaks at the landiolol and IS-1 retention times (Fig. 3) . Under optimized HPLC conditions (method 2), M-1 and IS-2 were separated with retention times of 12.9 and 27.8 min, respectively. Blank human blood from six volunteers showed no significant interfering peaks. But LLOQ sample showed an interfering peak near the M-1 peak at a retention time of 12.3 min. The interfering peak probably came from an impurity contained in IS-1 or IS-2, because blank sample showed no interfering peak and because blood sample spiked only IS showed same interfering peak (data not shown). Although this interfering peak could not be completely separated from the M-1 peak did not affect the M-1 quantitation by vertical separation (Table 1) .
Landiolol and M-1 had good linearity at concentrations ranging from 0.05 to 10 mg/ml and 0.1 to 20 mg/ml, respectively. The correlation coefficients (r) of landiolol and M-1 were not less than 0.995 in all cases. Table 1 shows the validation results for intra-and inter-day assay accuracy and precision. The accuracy and precision of landiolol and M-1 satisfied the acceptance criteria, and the analytical method gave reproducible intra-and inter-day accuracy and precision.
The stability test results are summarized in Table 2 . Landiolol and M-1 were considered stable if the RE (%) was no greater than Ϯ15%. Using these criteria, landiolol and M-1 were stable in human blood/ethanol up to 4 h at room temperature, up to 4 months at Ϫ20°C or Ϫ80°C, and in processed samples up to 72 h at 4°C. The y-axes in these figures is the same scale. 
CONCLUSIONS
Bioanalytical methods were validated to determine landiolol and its major metabolite, M-1, in human blood using an HPLC-UV detector. These analytes were recovered from the same blood sample using a multi-step extraction process and then determined with two different HPLC conditions. The validation study results indicated that we successfully established these methods with sufficient sensitivity and selectivity by optimizing multi-step extraction procedures and two HPLC conditions. The lower limits of quantification were 0.05 mg/ml for landiolol and 0.1 mg/ml for M-1. These methods were successfully applied to a pharmacokinetic study in humans 5, 6) and the characterization of blood pharmacokinetics of landiolol and M-1 at a therapeutic dosage. We think that these methods contribute to progress of clinical research of landiolol hydrochloride. 
